45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
12,927
Insurances with rates
9
CPT / HCPCS codes
11,835
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $99,806 | $88,983 | $192,797 | 6 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $99,806 | $180 | $192,797 | 23 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $54,248 | $48,366 | $104,792 | 6 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $54,248 | $58.66 | $104,792 | 23 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $52,202 | $46,541 | $100,840 | 6 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $52,202 | $139 | $100,840 | 23 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $48,492 | $43,234 | $93,674 | 6 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $48,492 | $134 | $93,674 | 23 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $37,739 | $33,647 | $72,901 | 6 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $37,739 | $155 | $72,901 | 23 |
| 33270 | HC INS/REP SUBC DEFIBRILLATOR | $68,318 | $32,183 | $62,169 | $62,169 | 1 |
| 33270 | HC INS/REP SUBC DEFIBRILLATOR | $68,318 | $32,183 | $5,386 | $63,000 | 22 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $31,383 | $27,980 | $60,623 | 6 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $31,383 | $254 | $60,623 | 23 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $30,673 | $27,346 | $59,251 | 6 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $30,673 | $89.43 | $59,251 | 23 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $29,932 | $26,686 | $57,820 | 6 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $29,932 | $28.19 | $57,820 | 23 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $62,016 | $29,214 | $26,047 | $56,434 | 6 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $62,016 | $29,214 | $36.01 | $56,434 | 23 |
| 0408T | HC INSJ/RPLC CARDIAC MODULIJ SYS | $61,232 | $28,845 | $55,721 | $55,721 | 1 |
| 0408T | HC INSJ/RPLC CARDIAC MODULIJ SYS | $61,232 | $28,845 | $5,386 | $63,000 | 22 |
| 0409T | HC INSJ/RPLC CAR MODULJ PLS GN | $61,232 | $28,845 | $55,721 | $55,721 | 1 |
| 0409T | HC INSJ/RPLC CAR MODULJ PLS GN | $61,232 | $28,845 | $5,386 | $55,721 | 22 |
| 0414T | HC RMVL & RPL CAR MODULJ PLS GN | $61,232 | $28,845 | $55,721 | $55,721 | 1 |
| 0414T | HC RMVL & RPL CAR MODULJ PLS GN | $61,232 | $28,845 | $5,386 | $55,721 | 22 |
| 33289 | HC TCAT IMPL WRLS P-ART PRS SNR | $57,990 | $27,318 | $52,771 | $52,771 | 1 |
| 33289 | HC TCAT IMPL WRLS P-ART PRS SNR | $57,990 | $27,318 | $5,386 | $55,861 | 22 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $27,238 | $23,128 | $52,616 | 6 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $27,238 | $106 | $52,616 | 22 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $27,059 | $24,125 | $52,270 | 6 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $27,059 | $53.71 | $52,270 | 23 |
| 37227 | HC REVASC FEMPOP STNT/ATHER | $56,282 | $26,514 | $51,217 | $51,217 | 1 |
| 37227 | HC REVASC FEMPOP STNT/ATHER | $56,282 | $26,514 | $5,386 | $51,217 | 22 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $26,188 | $23,348 | $50,587 | 6 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $26,188 | $13,058 | $50,587 | 14 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $24,630 | $21,960 | $47,579 | 6 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $24,630 | $92.5 | $47,579 | 23 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $23,594 | $21,036 | $45,577 | 6 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $23,594 | $21.68 | $45,577 | 23 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $47,856 | $22,544 | $43,549 | $43,549 | 1 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $47,856 | $22,544 | $11,241 | $43,549 | 14 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $47,856 | $22,544 | $43,549 | $43,549 | 1 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $47,856 | $22,544 | $11,241 | $43,549 | 14 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $47,856 | $22,544 | $43,549 | $43,549 | 1 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $47,856 | $22,544 | $11,241 | $43,549 | 14 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $47,856 | $22,544 | $43,549 | $43,549 | 1 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $47,856 | $22,544 | $11,241 | $43,549 | 14 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $47,856 | $22,544 | $43,549 | $43,549 | 1 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $47,856 | $22,544 | $11,241 | $43,549 | 14 |
Showing top 50 of 12,927 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.